Single intravenous XXXX dose to reduce @entity190 in primary total knee replacement.

@entity1 @entity548 @entity190 @entity927 @entity715
OBJECTIVE: To evaluate the effectiveness and safety of a single intravenous dose of @entity927 in order to reduce @entity190 in total knee replacement. MATERIALS AND METHODS: Prospective observational study of the administration of @entity927 in @entity1 undergoing primary total knee arthroplasty from November 2013 to February 2015, in which an autologous blood recovery system was used. The study included 98 @entity1 , distributed into two groups of 49 @entity1 according to whether or not they received intravenous @entity927 . The primary endpoint was the number of @entity1 requiring autologous transfusion from the recovery system autologous blood recovery system. RESULTS: No drop-outs were recorded during follow-up. There were no significant differences between groups as regards the preoperative and hospital variables. The mean preoperative haemoglobin and haematocrit at 24 and 48hours postoperatively were similar in both groups. The average volume of @entity548 in the autologous blood recovery system and estimated average @entity190 was lower in @entity1 who had been administered @entity927 , with significant differences. No @entity1 in the group that was administered @entity927 required blood autotransfusion. The transfusion rate was zero in the two groups. No adverse events related to the administration of @entity927 were recorded. CONCLUSIONS: Intravenous administration of @entity927 , according to the described protocol, has presented a non-autotransfusion or allo-transfusion rate of 100%, with no increased incidence of @entity715 events. Thus, its use in this group of @entity1 is recommended. The indication should be individualized, its use justified in the @entity1 medical records, and informed consent is mandatory.
